Maxigen BiotechTPE:1783 -1.55%87 Net Margin % is 37.27% as of Dec. 2025, which is 141% above its 10-year median of 15.48. GuruFocus rates TPE:1783 with a GF Score™ of 87/100 and a GF Value™ of NT$60.99 (Significantly Undervalued). Among 817 Medical Devices & Instruments companies, Maxigen Biotech ranks better than 96.21% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Maxigen Biotech's Net Income for the
three
months ended in Dec. 2025 was NT$83.7 Mil. Maxigen Biotech's Revenue for the
three
months ended in Dec. 2025 was NT$224.7 Mil. Therefore, Maxigen Biotech's net margin for the quarter that ended in Dec. 2025 was 37.27%.
The historical rank and industry rank for Maxigen Biotech's Net Margin % or its related term are showing as below:
TPE:1783'
s Net Margin % Range Over the Past 10 Years
Min: -3.64 Med: 15.48 Max: 32.69
Current: 32.69
TPE:1783's Net Margin % is ranked better than 96.21% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.09
vs TPE:1783: 32.69
Maxigen Biotech (TPE:1783) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Maxigen Biotech Net Margin % Related Terms
Maxigen Biotech Net Margin % Historical Data
* Premium members only.
The historical data trend for Maxigen Biotech's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1783 vs ISRG, BDX, MDLN: Net Margin % Comparison
For the Medical Instruments & Supplies subindustry, Maxigen Biotech's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maxigen Biotech Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's Net Margin % distribution charts can be found below:
* The bar in red indicates where Maxigen Biotech's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maxigen Biotech (TPE:1783) has a Net Margin % of 37.27% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Maxigen Biotech and its competitors. This is 141% above median its historical median of 15.48. According to the industry distribution chart, Maxigen Biotech ranks #31 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 3.8%.
Is Maxigen Biotech's Net Margin % too high?
Maxigen Biotech's current Net Margin % of 37.27% is 141% above median its 10-year median of 15.48. The Medical Devices & Instruments industry median Net Margin % is 2.09. Maxigen Biotech's value of 37.27% is 1683.3% above this industry median. Based on the distribution chart, Maxigen Biotech ranks #31 out of 817 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Maxigen Biotech has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maxigen Biotech's Net Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Maxigen Biotech ranks #31 out of 817 companies for Net Margin %. This places Maxigen Biotech in the top 4% of its industry — outperforming the majority of peers. The industry median Net Margin % is 2.09. Maxigen Biotech's value of 37.27% is 1683.3% above this benchmark. While the company's 10-year median is 15.48 vs. the industry median of 2.09, Maxigen Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.09, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maxigen Biotech's current Net Margin % of 37.27% is 1683.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Maxigen Biotech and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maxigen Biotech's current Net Margin % is 37.27%, which is 141% above median its own 10-year median of 15.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maxigen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$60.99, compared to a current price of NT$38.10 — trading 37.5% below its estimated fair value. The current Net Margin % is 37.27%, which is 141% above median its 10-year median of 15.48 and 1683.3% above the Medical Devices & Instruments industry median of 2.09. Maxigen Biotech's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current Net Margin % is 37.27% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maxigen Biotech (TPE:1783) Overvalued in 2026?
Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued.
The current stock price of NT$38.10 is trading 37.5% below its estimated GF Value™ of NT$60.99.
GuruFocus considers Maxigen Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1783:
Net Margin %: 37.27% (141% above median its 10-year median of 15.48)
GF Value™: NT$60.99 vs. price of NT$38.10 (37.5% below fair value)
Industry Position: 1683.3% above the Medical Devices & Instruments median (#31 of 817)
No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score
Get the complete analysis for TPE:1783
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1783 has been successfully added to your 
